CD28 and neuroblastoma: A fourth generation GD2 CAR (including CD28, 4-1BB, and CD27 costimulatory domains in addition to CD3ζ) is also being tested in a multi-institutional Chinese Phase II trial for high-risk neuroblastoma patients.